Page 23 - P4403.14-V106 July OTC Magazine NI 2025
P. 23
DIGESTIVE HEALTH 23
ARE YOUR
PATIENTS
TREATING THE
CAUSE OF THEIR
FREQUENT
HEARTBURN?
FREQUENT HEARTBURN
OCCURS MORE THAN
ONCE A WEEK
NO OTHER HEARTBURN
REMEDY LASTS LONGER
WITHOUT PRESCRIPTION 1,2
Esomeprazole
Heartburn is caused by stomach acid rising up (reflux)
into the oesophagus. Frequent heartburn makes the
oesophagus sensitive to acid so it doesn’t take much to
trigger the pain.
NICE guidelines recommend PPIs as first line treatment
for frequent heartburn. Nexium Control treats the cause
3
and symptoms of frequent heartburn by reducing the
production of stomach acid.
DISCOVER THE SCIENCE
OF NEXIUM CONTROL
1. Lind T et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol
Ther 2000; 14: 861-7 2. Rohss K et al. Esomeprazole 20mg provides more effective instragastric acid control than maintenance-dose rabeprazole, lansoprazole or
pantaprazole in healthy volunteers. Clin Drug Invest 2004; 24(1): 1-7. 3. NICE guidelines CG184 Sept 2014.
Nexium Control 20 mg gastro-resistant tablets. Active ingredient: Esomeprazole Indications: The short term treatment of reflux symptoms (e.g. heartburn and
acid regurgitation) in adults. Legal category: P: 28s tablets. PL holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K.
Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at:
https://www.medicines.org.uk/emc/product/14465/smpc
Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-NEX-23-00012.
Save
18% Off Product Size Buying RRP Trade POR Pip Code
Offer
Price/
%
%
Single
Trade NEXIUM 14 £6.77 £13.99 18% 42% 4049888
NEXIUM CONTROL 20MG CAP 14BTL 4EA-TY GB
NEXIUM CONTROL 20MG FCT 10X2X7 BLST S2 14 £6.29 £12.99 18% 42% 3883139
NEXIUM CONTROL 20MG FCT 12X1X7 BLST S2 7 £3.62 £7.49 18% 42% 3883147
09/06/2025 16:27:05
P4403.14-V106 July OTC Magazine 2025 NI.indd 23 09/06/2025 16:27:05
P4403.14-V106 July OTC Magazine 2025 NI.indd 23
